News Archive
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi with an intravenous and subcutaneous formulation approved by the FDA. The tocilizumab biosimilar provides increased access and an affordable, high-quality, and safe treatment option for U.S. patients.
Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and Subcutaneous tocilizumab biosimilar approved by the FDA
Tyenne® provides a comprehensive, accessible, and high-quality treatment option for U.S. patients treated with tocilizumab.
IDACIO® (adalimumab-aacf) Now Available in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)
The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.
Stimufend® (pegfilgrastim-fpgk) Now Available in the United States
Fresenius Kabi announced today the immediate availability in the U.S. of Stimufend®(pegfilgrastim-fpgk), the company’s biosimilar to Neulasta® (pegfilgrastim), for use in patients at risk for febrile neutropenia
Biosimilar Adalimumab-aacf Gains FDA Approval, Marks Growing Interest in Biosimilar Development
The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi’s long-term dedication to biosimilars.
